All In Biotech

Investigational drug · Phase 3

bypassing agents

Also called: Clotting factor concentrates, CFC, BPA

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hemophilia, Von Willebrand Disease, Type 3.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

13

Any phase or sponsor naming "bypassing agents"

First trial start

2023

Feb 1, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "bypassing agents", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hemophilia
  • Von Willebrand Disease, Type 3

Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "bypassing agents" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 20,243 on PubMed

Also in development for Hemophilia

  • STSP-0601Phase 31 trial

    Jiangsu BioJeTay Biotechnology Co., Ltd. · Hemophilia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.